[1]
O. Shonukan, A. Dantzig, S. Kloeker-Rhoades, and I. Garcia-Ribas, “Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas”, Hematol Meeting Rep, vol. 3, no. 1, Jun. 2009.